enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Natalizumab - Wikipedia

   en.wikipedia.org/wiki/Natalizumab

   Natalizumab, sold under the brand name Tysabri among others, is a medication used to treat multiple sclerosis and Crohn's disease. [9] It is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin . [ 9 ]

3. List of therapeutic monoclonal antibodies - Wikipedia

   en.wikipedia.org/wiki/List_of_therapeutic...

   cancer Amivantamab: Rybrevant: BsAb: human: Epidermal growth factor receptor (EGFR), cMet: Y: non-small cell lung cancer: Anatumomab mafenatox [17] Fab: mouse: Tumor-associated glycoprotein 72 (TAG-72) non-small cell lung cancer: Andecaliximab [18] mab: chimeric: gelatinase B: gastric cancer or gastroesophageal junction adenocarcinoma Anetumab ...

4. Monoclonal antibody therapy - Wikipedia

   en.wikipedia.org/wiki/Monoclonal_antibody_therapy

   Monoclonal antibodies used to boost an anticancer immune response is another strategy to fight cancer where cancer cells are not targeted directly. Strategies include antibodies engineered to block mechanisms which downregulate anticancer immune responses, checkpoints such as PD-1 and CTLA-4 ( checkpoint therapy ), [ 20 ] and antibodies ...

5. New TYSABRI® Data Show Earlier Treatment and Longer ... - AOL

   www.aol.com/news/2013-10-03-new-tysabri-data...

   New TYSABRI ® Data Show Earlier Treatment and Longer-Term Use Result in Significant Reductions in MS Disease Activity - Earlier Treatment with TYSABRI Demonstrated Reduction in Relapse Severity ...

6. Androgen deprivation therapy - Wikipedia

   en.wikipedia.org/wiki/Androgen_deprivation_therapy

   Androgen deprivation therapy (ADT), also called androgen ablation therapy or androgen suppression therapy, is an antihormone therapy whose main use is in treating prostate cancer. Prostate cancer cells usually require androgen hormones, such as testosterone, to grow. ADT reduces the levels of androgen hormones, with drugs or surgery, to prevent ...

7. STAMPEDE (clinical trial) - Wikipedia

   en.wikipedia.org/wiki/STAMPEDE_(clinical_trial)

   Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) is a clinical trial investigating treatments for high risk or terminal prostate cancer. Recruitment started in 2005 and ended in 2022; as of January 2020, over 10,000 participants had joined the trial.